Atherosclerosis is the build-up of fatty material (such as cholesterol), fibrous material and calcium). The build-up forms an atheroma (degeneration of the walls of the arteries) under the ...
There is no US Food and Drug Administration (FDA)-approved therapy for NASH, and, like atherosclerosis, its progressive pathology is largely irreversible. “As with atherosclerosis, the ...
Atherosclerosis is a chronic inflammatory process accounting for increased cardiovascular and cerebrovascular morbidity and mortality. A wealth of recent data has implicated several infectious ...
In summary, compelling data indicate that infection does contribute to atherogenesis and to the acute complications of atherosclerosis caused by plaque rupture. What has clearly emerged over the ...
A cancer therapy that prompts the body's immune defenses against viruses and bacteria to attack tumors can make patients more ...
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...
Sagimet Biosciences (SGMT) announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase ...